BACKGROUND:Xerostomia (dry mouth) after head/neck radiation is a common problem among cancer patients. Quality of life (QOL) is impaired, and available treatments are of little benefit. This trial determined the feasibility of conducting a sham-controlled trial of acupuncture and whether acupuncture could prevent xerostomia among head/neck patients undergoingradiotherapy. METHODS: A sham controlled, feasibility trial was conducted at Fudan University Shanghai Cancer Center, Shanghai, China among patients with nasopharyngeal carcinoma undergoing radiotherapy. To determine feasibility of a sham procedure, 23 patients were randomised to real acupuncture (N=11) or to sham acupuncture (N=12). Patients were treated three times/week during the course of radiotherapy. Subjective measures were the Xerostomia Questionnaire (XQ) and MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN). Objective measures were unstimulated whole salivary flow rates (UWSFR) and stimulated salivary flow rates (SSFR). Patients were followed for 1 month after radiotherapy. RESULTS:XQ scores for acupuncture were significantly lower than sham controls starting in week 3 and lasted through the 1-month follow-up (all P's <0.001 except for week 3, which was 0.006), with clinically significant differences as follows: week 6 - RR 0.28 [95% confidence interval, 0.10, 0.79]; week 11 - RR 0.17 [95%CI, 0.03, 1.07]. Similar findings were seen for MDASI-HN scores and MDASI-Intrusion scores. Group differences for UWSFR and SSFR were not found. CONCLUSIONS: In this small pilot study, true acupuncture given concurrently with radiotherapy significantly reduced xerostomia symptoms and improved QOL when compared with sham acupuncture. Large-scale, multi-centre, randomised and placebo-controlled trials are now needed.
RCT Entities:
BACKGROUND:Xerostomia (dry mouth) after head/neck radiation is a common problem among cancerpatients. Quality of life (QOL) is impaired, and available treatments are of little benefit. This trial determined the feasibility of conducting a sham-controlled trial of acupuncture and whether acupuncture could prevent xerostomia among head/neck patients undergoing radiotherapy. METHODS: A sham controlled, feasibility trial was conducted at Fudan University Shanghai Cancer Center, Shanghai, China among patients with nasopharyngeal carcinoma undergoing radiotherapy. To determine feasibility of a sham procedure, 23 patients were randomised to real acupuncture (N=11) or to sham acupuncture (N=12). Patients were treated three times/week during the course of radiotherapy. Subjective measures were the Xerostomia Questionnaire (XQ) and MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN). Objective measures were unstimulated whole salivary flow rates (UWSFR) and stimulated salivary flow rates (SSFR). Patients were followed for 1 month after radiotherapy. RESULTS: XQ scores for acupuncture were significantly lower than sham controls starting in week 3 and lasted through the 1-month follow-up (all P's <0.001 except for week 3, which was 0.006), with clinically significant differences as follows: week 6 - RR 0.28 [95% confidence interval, 0.10, 0.79]; week 11 - RR 0.17 [95%CI, 0.03, 1.07]. Similar findings were seen for MDASI-HN scores and MDASI-Intrusion scores. Group differences for UWSFR and SSFR were not found. CONCLUSIONS: In this small pilot study, true acupuncture given concurrently with radiotherapy significantly reduced xerostomia symptoms and improved QOL when compared with sham acupuncture. Large-scale, multi-centre, randomised and placebo-controlled trials are now needed.
Authors: J C Horiot; F Lipinski; S Schraub; C Maulard-Durdux; R J Bensadoun; J M Ardiet; M Bolla; Y Coscas; F Baillet; B Coche-Dequéant; M Urbajtel; X Montbarbon; S Bourdin; M Wibault; M Alfonsi; G Calais; P Desprez; F Pene; M Lapeyre; J Vinke; J Maral Journal: Radiother Oncol Date: 2000-06 Impact factor: 6.280
Authors: T Wasserman; J I Mackowiak; D M Brizel; W Oster; J Zhang; P J Peeples; R Sauer Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: V Rudat; J Meyer; F Momm; M Bendel; M Henke; V Strnad; K Grötz; A Schulte Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: M Kay Garcia; Jennifer McQuade; Richard Lee; Robin Haddad; Michael Spano; Lorenzo Cohen Journal: Curr Oncol Rep Date: 2014-12 Impact factor: 5.075
Authors: Donald Abrams; Michael McCulloch; Misha Cohen; Mike Liaw; Deborah Silverman; Carla Wilson Journal: Integr Cancer Ther Date: 2017-01-05 Impact factor: 3.279
Authors: Branden A Smeester; Mona Al-Gizawiy; Elaine E O'Brien; Marna E Ericson; Jennifer L Triemstra; Alvin J Beitz Journal: Evid Based Complement Alternat Med Date: 2013-10-21 Impact factor: 2.629